Migraine trials recruiting in Georgia

All Migraine trials nationally

Cities in Georgia

Recruiting trials in Georgia

• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
  NCT07018713 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Decatur
• A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
  NCT07018700 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Decatur
• A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07674654 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Georgia: Atlanta, Marietta, Stockbridge
• A Pivotal Clinical Study to Evaluate the MySalvia System for the Treatment of Resistant Migraine
  NCT07719608 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 84 Years · Sex: All (male and female) · Georgia: Newnan
• A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
  NCT04965675 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta
• A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
  NCT05897320 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta
• A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
  NCT05711394 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Georgia: Brunswick
• A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
  NCT06625060 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Georgia: Atlanta
• A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
  NCT07645924 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Georgia: Atlanta, Marietta, Stockbridge
• A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
  NCT06641466 · Phase: Phase 3 · Ages: 18 Years to 45 Years · Sex: Female · Georgia: Marietta, Stockbridge
• A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
  NCT06995729 · Phase: Phase 1 · Ages: 6 Years to 11 Years · Sex: All (male and female) · Georgia: Hinesville
• Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
  NCT05156398 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Georgia: Augusta, Sandy Springs, Savannah, Snellville
• Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
  NCT04743141 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta, Brunswick, Decatur
• Randomized Study in Children and Adolescents With Migraine: Acute Treatment
  NCT04649242 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta, Brunswick, Decatur
• Responding With Evidence and Access for Childhood Headaches
  NCT05889624 · Phase: Not applicable (e.g. observational or device study) · Ages: 10 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta
• Study of EVO756 in Adults With Migraine
  NCT07616128 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Georgia: Decatur
• Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
  NCT05125302 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Georgia: Atlanta, Brunswick, Decatur, Savannah